Software Engineer

Berkeley, California, United States

Auto‑apply with AI Apply

$100,000 – $162,500Compensation

Entry Level & New Grad, Junior (1 to 2 years), Mid-level (3 to 4 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Data & AnalyticsIndustries

Requirements

Candidates should possess a Bachelor's or Master's degree in computer science, data science, engineering, or a related field, with 0-4 years of experience. Expertise in one or more programming languages such as Python is required, along with experience with web services and application frameworks like Flask or Django. A solid understanding of database concepts and familiarity with SQL is also necessary, as is familiarity with scripting and cheminformatics toolkits like RDKit, OEChem, or Chemaxon. Experience with cloud computing services like GCP or AWS, and versioning software such as Github, is beneficial.

Responsibilities

The Software Engineer will develop and deploy software tools for processing, analyzing, and organizing scientific data, manage and maintain a commercial database for assays, inventory, and compound data, collaborate with a machine learning team to train and deploy STOA ML models, collaborate with lab scientists including chemistry and automation teams to develop custom tools for their workflows, automate data capture from laboratory instruments, and maintain internally developed software packages.

Skills

Python

Flask

Django

SQL

RDKit

OEChem

Chemaxon

GCP

AWS

Github

Data Analysis

Machine Learning

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free